{"id":"NCT00291226","sponsor":"Yale University","briefTitle":"Glycine vs Placebo for the Schizophrenia Prodrome","officialTitle":"Glycine vs Placebo for the Schizophrenia Prodrome","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2006-03","primaryCompletion":"2009-07","completion":"2009-07","firstPosted":"2006-02-13","resultsPosted":"2016-12-29","lastUpdate":"2020-04-02"},"enrollment":8,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia Prodrome"],"interventions":[{"type":"DRUG","name":"Glycine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Glycine","type":"EXPERIMENTAL"},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR"}],"summary":"Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.","primaryOutcome":{"measure":"Scale of Prodromal Symptoms Total Score","timeFrame":"Baseline","effectByArm":[{"arm":"Glycine","deltaMin":37.8,"sd":15.3},{"arm":"Placebo Group","deltaMin":37.5,"sd":10}],"pValues":[]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["23089076"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":4},"commonTop":["Sedation","Disturbed Sleep","Irritability","Orgasm Dysfunction","Malaise"]}}